Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS other · 2025-06-06

Clinical Trial Update: Telitacicept for the Treatment of Refractory RA [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Telitacicept for refractory rheumatoid arthritis is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Telitacicept

Snippet

Sponsor: Chinese SLE Treatment And Research Group | Conditions: Rheumatoid Arthritis (RA) | Phase 4 | Status: NOT_YET_RECRUITING